Case report: Enfortumab vedotin induced refractory DKA and multi organ failure – a rare fatal adverse event

There are very few therapeutic options to treat patients with locally advanced or metastatic Urothelial Cancer (UC). Enfortumab vedotin (EV) was recently approved by the FDA and has become a new therapeutic option for patients previously managed with conventional treatments. Despite its efficacy, EV...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	Astha Koolwal Kapoor, Carleton S. Ellis, Deepali Pandey, Derek B. Allison, Zin W. Myint
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	Frontiers Media S.A. 2024-02-01
Cyfres:	Frontiers in Oncology
Pynciau:	diabetes ketoacidosis CRRT insulin enfortumab vedotin maculopapular rash liver failure
Mynediad Ar-lein:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1332478/full
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!